respective terms of the notes to interest expense, net in the condensed consolidated statements of earnings.
AbbVie used the net proceeds received from the issuance of the notes to finance the acquisition of ImmunoGen, repay its term-loan, repay commercial paper borrowings, pay fees and expenses in respect of the foregoing, finance general corporate purposes and, together with cash on hand, fund AbbVie’s acquisition of Cerevel Therapeutics.
In December 2023, AbbVie entered into a $
9.0
billion 364-day bridge credit agreement and $
5.0
billion 364-day term loan credit agreement. In February 2024, AbbVie borrowed and repaid $
5.0
billion under the term loan credit agreement. Interest charged on this borrowing was based on Secured Overnight Financing Rate Reference Rate (SOFR) +
0.975
% with an effective interest rate of
6.29
%. Subsequent to the $
15.0
billion issuance of senior notes, AbbVie terminated both the bridge and term loan credit agreements in the first quarter of 2024. In February 2024, concurrent with the ImmunoGen acquisition, the company assumed and repaid an ImmunoGen senior secured term loan at a fair value of $
99
million.
Note 9
Post-Employment Benefits
The following table summarizes net periodic benefit cost relating to the company’s defined benefit and other post-employment plans:
The components of net periodic benefit cost other than service cost are included in other expense, net in the condensed consolidated statements of earnings.
Note 10
Equity
Stock-Based Compensation
Stock-based compensation expense is principally related to awards issued pursuant to the AbbVie 2013 Incentive Stock Program and the AbbVie Amended and Restated 2013 Incentive Stock Program and is summarized as follows:
In addition to stock-based compensation expense included in the table above and in connection with the acquisition of ImmunoGen, AbbVie incurred cash-settled, post-closing expense for ImmunoGen employee incentive awards, which is summarized in the table below:
Stock Options
During the three months ended March 31, 2025, primarily in connection with the company's annual grant, AbbVie granted
0.6
million stock options with a weighted-average grant-date fair value of $
38.39
. As of March 31, 2025, $
12
million of unrecognized compensation cost related to stock options is expected to be recognized as expense over approximately the next
two years
.
RSUs and Performance Shares
During the three months ended March 31, 2025, primarily in connection with the company's annual grant, AbbVie granted
4.7
million RSUs and performance shares with a weighted-average grant-date fair value of $
193.46
. As of March 31, 2025, $
1.1
billion of unrecognized compensation cost related to RSUs and performance shares is expected to be recognized as expense over approximately the next
two years
.
Cash Dividends
The following table summarizes quarterly cash dividends declared during 2025 and 2024:
Stock Repurchase Program
The company's stock repurchase authorization